Drug Discovery & Development | Teva Gets Additional Exclusivity for Treanda Drug Discovery & Development ... Administration (FDA) has granted orphan drug exclusivity for Treanda through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. FDA grants Teva's Treanda orphan drug status Cancer drug Treanda gets orphan status, but that won't save Teva's shrinking ... Teva Pharmaceutical Industries Limited : Teva Announces Additional Regulatory ... |
